Miltenyi Biotec, Inc.

Miltenyi Biotec, Inc., a foreign-owned for-profit manufacturer headquartered in Auburn, California, supplies specialized cell separation, analysis, and processing instruments and proprietary reagents to federal research agencies primarily as a prime contractor under full-and-open competitive procurement. The company competes predominantly without set-asides and holds extensive federal contract work concentrated within the National Institutes of Health ecosystem, with over 1,368 total awards recorded across 68 distinct customer agencies.

Miltenyi Biotec's core federal capability centers on manufacturing and servicing GentleMACS Octo Dissociators, MACSQuant flow cytometers and cell sorters, AutoMACS NEO separators, CliniMACS automated cell isolation systems, and associated consumables—proprietary reagents, microbeads, tubing, and cell culture media—that support Good Manufacturing Practice-compliant cell therapy manufacturing and biomedical research applications. Representative work includes a $5.77 million single-award indefinite delivery contract with the NIH Clinical Center (awarded June 26, 2023, running through September 30, 2026) supplying CliniMACS cell isolation reagents and consumables for investigational cell therapy products across over 50 intramural clinical trials; a $749.17 million firm fixed-price purchase order from the FDA for a MACSima imaging system (awarded August 8, 2023, completion March 31, 2029); a $450.99 million purchase order from NIAID for a MACSima platform including imaging system, starter kit, installation, training, and software license (awarded September 26, 2024); and a $396.56 million purchase order from the National Institute on Drug Abuse for a light-sheet microscope system for 3D imaging (awarded September 21, 2022). Task order activity against the parent IDC vehicle with NIH Clinical Center includes a $500,000 delivery order (January 1, 2026) and a $200,000 option-year funding increment (March 13, 2026).

Customer concentration is heavily skewed toward NIH components. The NIH Clinical Center alone accounts for 87 awards valued at $23.7 million combined potential value and anchors the top-customer list by dollars, followed at distance by the NIH Office of the Chief Operating Officer (25 awards, $4.2 million), NIAID (102 awards, $3.8 million), and the National Cancer Institute (134 awards, $3.1 million). Across the top five funding agencies by count, coverage reaches 39% of all awards. When ranked by potential value, the same five agencies represent 59% of combined potential value, indicating that while NIH units place many small orders (reagent, maintenance, and equipment purchases in the $10,000–$50,000 range), the Clinical Center's large IDC drives dollar concentration.

Activity has declined markedly year over year—44 awards in 2022, 57 in 2023, 34 in 2024, 13 in 2025, and 14 in 2026 to date—reflecting a shift toward larger-value parent vehicles and fewer small transactional purchases. Within the next twenty-four months, 15 awards (combined potential value $1.3 million) reach ultimate completion date, creating modest recompete exposure, primarily among maintenance agreements and smaller consumables orders.

Miltenyi Biotec's parent-vehicle footprint centers on the NIH Clinical Center IDC (HHSN269201700011I, 6 task orders, $7.3 million combined value) and a Department of Defense Blanket Purchase Agreement (W81XWH17A0017, 5 task orders, $69 thousand). The company also places orders under an Office of Logistics and Acquisition Operations IDC (75N90023D00015, 2 task orders, $1.9 million combined value).

The vendor's NAICS concentration aligns with its product portfolio: Analytical Laboratory Instrument Manufacturing leads with 440 awards, followed by Other Electronic and Precision Equipment Repair and Maintenance (113 awards) and In-Vitro Diagnostic Substance Manufacturing (111 awards). PSC coding mirrors this distribution, with Laboratory Equipment and Supplies dominating at 658 awards and Maint/Repair/Rebuild of Equipment—Instruments and Laboratory Equipment at 251 awards.

Miltenyi Biotec holds one recorded subcontract engagement: a sub-award under Illumina, Inc. (June 20, 2024) for provision of products and solutions for cell and gene therapy applications in the context of COVID-19 serology testing services.

The vendor's federal footprint reflects its role as a specialized, proprietary supplier of mission-critical cell therapy manufacturing equipment and reagents to the NIH Clinical Center's translational research and clinical trial manufacturing mission. The sharp decline in award count year over year and modest recompete cliff suggest a transition from fragmented small purchases to consolidated, longer-term parent vehicles—a posture consistent with sole-source procurement authority justified by lack of alternative suppliers for proprietary CliniMACS systems and consumables.